Neurogene Inc. (NGNE) Stock: Price, Forecast & Analyst Target
Neurogene Inc. (NGNE) — MoonshotScore 52/100 (Fair band), calculated Nov 18, 2026. Price $22.15 (-3.40%), as of the Nov 20, 2026 trading session; market cap $459M.
Educational signal · not a buy or sell recommendation · How to read this
Neurogene Inc. · NGNE · NASDAQ
Neurogene Inc. is a biotechnology company focused on developing genetic medicines for neurological diseases. Their primary focus is on advancing gene therapies for rare and devastating conditions like Rett syndrome and Batten disease.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Neurogene (NGNE)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Stalling growth and a full valuation, though quality is only middling. Business Quality: Average; Financial Safety: Sound; Valuation: Full; Growth Durability: Shrinking; Momentum: Quiet.
- EPS beat 5 of the last 8 reports
- Altman Z 7.88 · Piotroski F 2
- ROE -44.4% · ROA -31.5% · current ratio 19.97 · earnings yield -18.0% · free-cash-flow yield -25.6%
Holding back: soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 50 | Fair | |
| 49 | Fair | |
| 49 | Fair | |
| 52 | Fair | |
| 52 | Fair | |
| 52 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $22.15 | |
| Change on the day | -3.40% | |
| Market capitalisation | $459M | — |
| Shares traded on the day | 178.3K |
Price & events
Other perspectives
Council score for Neurogene (NGNE): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Neurogene (NGNE), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Neurogene Inc. (NGNE) is listed on NASDAQ. It employs 131 people. The market values it at $459M.
What do the latest results show for Neurogene (NGNE)?
Short answer · as of
Against analyst estimates the company has EPS beat 5 of the last 8 reports.
What are the financial strengths and risks for Neurogene (NGNE)?
Short answer · as of
What is holding it back is soft growth. The distress and quality screens read Altman Z 7.88 · Piotroski F 2. Trailing ratios: ROE -44.4% · ROA -31.5% · current ratio 19.97 · earnings yield -18.0% · free-cash-flow yield -25.6%.
Data-derived red flags
- Negative return on equity (-44.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at Neurogene (NGNE)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $462,500 · EPS -5.11 · 9 analysts. Current published price targets run low $65.00 · high $81.00 · consensus $72.00 · median $70.00 against a quoted price of $22.15 (as of Nov 20, 2026).
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- No quarterly income statement is held for NGNE.
Checked against the records this page reads, on the dates shown above.
How does Neurogene compare with its peers?
Short answer
Neurogene's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $18.41 Nov 20, 2026 | $1.31B | 96 5-pillar Nov 18, 2026 | |
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 18, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 18, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 88 5-pillar Nov 18, 2026 | |
| $11.54 Nov 20, 2026 | $817M | 69 5-pillar Nov 18, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 69 5-pillar Nov 18, 2026 | |
| $38.85 Nov 20, 2026 | $1.26B | 69 5-pillar Nov 18, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 18, 2026 | |
| $19.19 Nov 20, 2026 | $1.18B | 66 5-pillar Nov 18, 2026 | |
| $30.43 Nov 20, 2026 | $1.02B | 64 5-pillar Nov 18, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 63 5-pillar Nov 18, 2026 | |
| Neurogene (NGNE) — this page | $22.15 | $459M | 52 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $65.00 – $81.00
- Consensus target
- $72.00
- Median target
- $70.00
- Revenue estimate
- $462,500
- EPS estimate
- $-5.11
Consensus record · Captured .
Measured against a quoted price of $22.15 (as of Nov 20, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held NGNE in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported NGNE in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About NGNE
These answers are editorial: 1 of these 9 answers is drawn from the NGNE research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for NGNE?
NGNE carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Neurogene Inc. is a biotechnology company focused on developing genetic medicines for neurological diseases.
Is NGNE a good stock to buy?
Stock Expert AI does not rate NGNE buy, sell or hold. Neurogene Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the NGNE stock price today?
The last price recorded for Neurogene Inc. (NGNE), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the NGNE price target?
The analyst consensus price target for Neurogene Inc. (NGNE), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for NGNE?
The main risks for Neurogene Inc. include the inherent challenges of drug development, such as clinical trial failures, regulatory hurdles, and competition from other biotechnology companies.
What are the key factors to evaluate for NGNE?
Neurogene Inc. (NGNE) holds a MoonshotScore in the moderate range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Timeline: Ongoing, with potential new partnerships announced within the next year. Not financial advice.
How frequently does NGNE data refresh on this page?
NGNE's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven NGNE's recent stock price performance?
Neurogene Inc. (NGNE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on rare neurological diseases with high unmet need. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NGNE overvalued or undervalued right now?
Neurogene Inc. (NGNE) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 9 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com